MEDICAL MARIJUANA, INC. INVESTMENT AXIM® BIOTECHNOLOGIES, INC. SECURES FUNDING TO CONTINUE PHARMA CLINICAL TRIALS PROGRAM IN CANNABINOID R&D
Financing Enables Cannabinoid Innovator to Continue Phase I-II Trials Of Numerous Intellectual Property (IP) Protected Cannabinoid-Based Products for Multiple Indications
Medical Marijuana, Inc. (OTC: MJNA) today announced that its portfolio company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has secured private funding to continue its pharmaceutical clinical trials program in cannabinoid research and development for multiple indications.
AXIM® Biotech’s most recent financing enables it to continue in the research and development of innovative pharmaceutical delivery systems and API (active pharmaceutical ingredients) for treatment of conditions for which there is currently no effective remedy. These indications currently include near term prospects for: MedChew, a cannabinoid-medicated chewing gum involving pain and spasticity in multiple sclerosis (MS) which will soon undergo clinical trials in Europe; then for a topical application of the cannabinoid, Cannabigerol, for psoriasis and atopic dermatitis (eczema) which is also being initially developed in European markets.
Other indications within AXIM's future plans for future cannabinoid-based clinical development include: Parkinson’s disease, Alzheimer’s disease/dementia, attention deficit hyper-activity disorder, (ADHD), psychosis, post-traumatic stress disorder (PTSD), autism, restless leg syndrome, glaucoma, inflammatory bowel disease, irritable bowel syndrome, Crohn’s disease.
“We’re extremely pleased that AXIM has received the financing it needs to continue clinical efforts with the Company's two near-term prospects. Further, the financing will allow the AXIM team of visionaries and world leaders, with proven track records, to create further cannabinoid-based innovations that may address additional indications,” said Medical Marijuana, Inc. Chief Executive Officer Dr. Stuart Titus.
“AXIM Biotech’s cannabinoid-based innovations in the extremely promising space of these novel therapeutics will provide consumers with a wide variety of new options worldwide. We salute and support the AXIM Biotech team in their clinical efforts and believe their delivery method for cannabinoids will provide a therapeutically improved delivery for future cannabinoid-based pain medication.”
An AXIM® Biotech breakthrough invention on pace to be fully registered by the EMA and FDA by the end of 2018 is the world’s first patented cannabinoid controlled-release chewing gum: MedChew Rx™. Recently featured by Reuters global news agency, MedChew Rx™ will change the way that medicine is delivered to patients worldwide. Directly compared to a sublingually delivered cannabis-based product currently on the market for multiple sclerosis (MS) in the Reuters article, the potential economic impact for MedChew Rx™ is estimated at $4.8 billion USD – for spasticity and pain associated with MS.
Axim will be conducting a clinical trial on MedChew Rx™ at the Free University of Amsterdam, The Netherlands in collaboration with the University of Plymouth, UK as well as an academic center in the USA for a novel, patented delivery form of cannabinoids for the treatment of chronic pain and spasticity in patients with multiple sclerosis. The anticipated duration of the trials prior to FDA/ EMA registration is approximately 12 months.
AXIM’s pipeline of intellectual property (IP) protected cannabinoid-based products include:
- MedChew Rx™ - THC/CBD cannabinoid controlled-release functional chewing gum to address pain and muscle spasticity in multiple sclerosis (MS) patients as well as numerous indication extensions based on the proprietary delivery platform
- RENECANN™ - the world’s first cannabigerol (CBG)-based skincare product line
- ORAXIMAX™ - the world’s first CBG-based oral care product line
- Suppocann™ - a suppository cannabinoid-release product for GI conditions such as IBD, IBS and Crohn’s disease
- Ophthocann™ and Cannbleph™ - cannabinoid-based products for reduction of intraocular pressure and for relief of conjunctivitis
###
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc
Investor Relations Contact:
EquiNet, LLC
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: info@equinet.us
www.equinet.us
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
About AXIM®
AXIM® Biotechnologies, Inc. (OTC: AXIM) is an innovative biotechnology Company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
LEGAL DISCLOSURE
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Tags: